The use of remdesivir outside of clinical trials during the COVID-19 pandemic

• Päätekijät: Vesa Halimi (Tekijä), Armond Daci (Tekijä), Nevenka Ridova (Tekijä), Irina Panovska-Stavridis (Tekijä), Milena Stevanovic (Tekijä), Venko Filipce (Tekijä), Aleksandar Dimovski (Tekijä), Aleksandra Grozdanova (Tekijä)
• Aineistotyyppi: Kirja
• Julkaistu: Taylor & Francis Group, 2020-12-01T00:00:00Z.
• Aiheet: article
• Linkit: Connect to this object online.

With a scientific background from filoviruses, paramyxoviruses, SARS-CoV, and MERS-CoV, remdesivir entered into the COVID-19 battle to become one of the favorable therapeutic candidates with potential antiviral activity in the treatment of this disease. Globally, remdesivir was accessed and investig...